**Supplementary figure A** **A systematic review and meta-analysis of the therapeutic equivalence of statins**




Weng TC, *et al. J Clin Pharm Ther* . 2010;35:139-151
Mukhtar RY, *et Al. Int J Clin Pract* . 2055;59(2):239-252

ATOR = atorvastatin; FLUVA = fluvastatin; LOVA = lovastatin; PRAVA = pravastatin; SIMVA = simvastatin; ROSU = rosuvastatin; PITA = pitavastatin.

**Supplementary Table A** **Percentage reduction of low-density lipoprotein-cholesterol (LDL-C) requested to achieve goals as a function of the starting value**

| Starting LDL-C | | Reduction to reach LDL-C goal, % | | |
|---|---|---|---|---|
| mmol/L | ~mg/dL | <1.8 mmol/L (~70 mg/dL) | <2.6 mmol/L (~100 mg/dL) | <3 mmol/L (~115 mg/dL) |
| >6.2 | >240 | >70 | >60 | >55 |
| 5.2–6.2 | 200–240 | 65–70 | 50–60 | 40–55 |
| 4.4–5.2 | 170–200 | 60–65 | 40–50 | 30–45 |
| 3.9–4.4 | 150–170 | 55–60 | 35–40 | 25–30 |
| 3.4–3.9 | 130–150 | 45–55 | 25–35 | 10–25 |
| 2.9–3.4 | 110–130 | 35–45 | 10–25 | <10 |
| 2.3–2.9 | 90–110 | 22–35 | <10 | – |
| 1.8–2.3 | 70–90 | <22 | – | – |

**Supplementary figure B** **HIV-drug interaction database of the University of Liverpool**

**Lipid-Lowering Treatment Selector**

*Charts revised August 2013. Full information available at www.hiv-druginteractions.org and www.hiv-druginteractionslite.org*

| | | ATV/r | DRV/r | FPV/r | IDV/r | LPV/r | SQV/r | EFV | ETV | NVP | RPV | MVC | EVG/c | RAL | ABC | FTC | 3TC | TDF | ZDV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Statins | Atorvastatin | ↑ | ↑ | ↑153% | ↑ | ↑490% | ↑ | ↓43% | ↓37% | ↓ | ↔ | ↔ | ↑ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ |
| | Fluvastatin | ↔ | ↔ | ↔ | ↑ | ↔ | ↑ | ↑ | ↑ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ |
| | Lovastatin | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↓ | ↓ | ↓ | ↔ | ↔ | ↑ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ |
| | Pravastatin | ↔ | ↑81% | ↔ | ↑ | ↔ | ↓50% | ↓44% | ↓ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ |
| | Rosuvastatin | ↑213% | ↑48% | ↑8% | ↑ | ↑107% | ↑ | ↔ | ↑ | ↔ | ↔ | ↔ | ↑48% | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ |
| | Simvastatin | ↑ | ↑ | ↑ | ↑ | ↑ | ↑ | ↓68% | ↓ | ↓ | ↔ | ↔ | ↑ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ |
| Fibrates | Bezafibrate | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ |
| | Clofibrate | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↑⇑ | ↔ |
| | Fenofibrate | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ |
| | Gemfibrozil | ↓ | ↓ | ↓ | ↓ | ↓41% | ↓ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↑ | ↔ | ↔ | ↔ | ↔ | ↔ |
| | Ezetimibe | ↑[a] | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ | ↔ |

**Colour Legend**

No clinically significant interaction expected.

These drugs should not be coadministered.

Potential interaction which may require a dosage adjustment or close monitoring.

Potential interaction predicted to be of weak intensity (<2 fold ↑AUC or <50% ↓AUC). No *a priori* dosage adjustment is recommended.

**Text Legend**

↑ Potential increased exposure of the lipid-lowering drug

↓ Potential decreased exposure of the lipid-lowering drug

↔ No signficant effect

⇑ Potential increased exposure of HIV drug

⇓ Potential decreased exposure of HIV drug

[a]Unboosted atazanavir

Numbers refer to increased or decreased AUC of the lipid-lowering drug as observed in drug-drug interaction studies.

(From Liverpool HIV Pharmacology Group, University of Liverpool)

**Supplementary Figure C Algorithm for treatment of muscular symptoms during statin treatment.[211]**




CETP = cholesteryl ester transfer protein; CK = creatine kinase; LDL-C= low-density lipoprotein cholesterol; PCKS9 = propotein onvertase subtilisin/kesin type 9; ULN = upper limit of the normal range.

[a]Efficacious statin such as atorvastatin or rosuvastatin.

*Reiner Z *et al.* (2011).